Published Erratum
doi: 10.1093/ndt/gfab349.
Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)
Affiliations
- PMID: 35146511
- PMCID: PMC8951194
- DOI: 10.1093/ndt/gfab349
Item in Clipboard
Published Erratum
Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)
Nephrol Dial Transplant.
.
No abstract available
Erratum for
-
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).Nephrol Dial Transplant. 2021 Aug 27;36(9):1616-1628. doi: 10.1093/ndt/gfab191. Nephrol Dial Transplant. 2021. PMID: 34077510 Free PMC article. Clinical Trial.
Similar articles
-
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.Nephron. 2020;144(8):372-382. doi: 10.1159/000508100. Epub 2020 Jun 24. Nephron. 2020. PMID: 32580188 Free PMC article. Clinical Trial.
-
Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia.World J Clin Cases. 2021 Sep 16;9(26):7682-7692. doi: 10.12998/wjcc.v9.i26.7682. World J Clin Cases. 2021. PMID: 34621819 Free PMC article.
-
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31340089 Clinical Trial.
-
Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.Pharmacol Res. 2020 May;155:104747. doi: 10.1016/j.phrs.2020.104747. Epub 2020 Mar 17. Pharmacol Res. 2020. PMID: 32171893
-
Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.Front Med (Lausanne). 2021 Aug 31;8:724456. doi: 10.3389/fmed.2021.724456. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34532333 Free PMC article.
Cited by
-
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin.Kidney Int Rep. 2021 Jun 9;6(10):2540-2553. doi: 10.1016/j.ekir.2021.05.028. eCollection 2021 Oct. Kidney Int Rep. 2021. PMID: 34622095 Free PMC article. Review.
-
HIF-PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses.Cancer Immunol Immunother. 2025 May 9;74(7):192. doi: 10.1007/s00262-025-04067-3. Cancer Immunol Immunother. 2025. PMID: 40343532 Free PMC article.
-
Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. Cochrane Database Syst Rev. 2022. PMID: 36005278 Free PMC article.
-
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.Front Med (Lausanne). 2021 Mar 26;8:642296. doi: 10.3389/fmed.2021.642296. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33842503 Free PMC article. Review.
-
Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.Kidney Int Suppl (2011). 2021 Apr;11(1):8-25. doi: 10.1016/j.kisu.2020.12.002. Epub 2021 Mar 18. Kidney Int Suppl (2011). 2021. PMID: 33777492 Free PMC article.
